Stockscreener 앱 받기
57.75
0.54%
0.31
전일 마감가:
$57.44
열려 있는:
$58
하루 거래량:
1.22M
Relative Volume:
0.79
시가총액:
$7.35B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
19.12
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-0.93%
1개월 성능:
+3.24%
6개월 성능:
-7.11%
1년 성능:
+50.55%
1일 변동 폭
$57.32
$58.74
1주일 범위
$56.07
$60.67
52주 변동 폭
$37.73
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
57.75 | 7.35B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products - MSN
SEC Form 4 filed by PRESIDENT AND CEO Torley Helen - Quantisnow
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth - MSN
Meitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - Simply Wall St
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts - Benzinga
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Kestra Private Wealth Services LLC Sells 9,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript - Insider Monkey
Kornitzer Capital Management Inc. KS Has $10.19 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by Convergence Investment Partners LLC - MarketBeat
Halozyme stock target raised to $78 at JMP Securities - Investing.com India
Halozyme stock target raised to $78 at JMP Securities By Investing.com - Investing.com Nigeria
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... By GuruFocus - Investing.com Canada
Halozyme Therapeutics: Q4 Earnings Snapshot - CT Insider
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... - Yahoo Finance
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates - MSN
Halozyme Therapeutics Inc (HALO) Q4 Earnings: EPS of $1.06 Beats - GuruFocus.com
Halozyme Therapeutics Q4 2024 Earnings Preview - MSN
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Halozyme Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Halozyme shares surge 6% on strong Q4 results, upbeat 2025 outlook - Investing.com Nigeria
Earnings Flash (HALO) Halozyme Therapeutics Reports Q4 Adjusted EPS $1.26, vs. FactSet Est of $1.13 - Marketscreener.com
Halozyme Therapeutics Reiterates FY 2025 Guidance For EPS of $4.95-$5.35 on Revenue of $1.15-$1.225 Billion, vs FactSet Analyst Consensus of $4.90/Share on Revenue of $1.19 Billion - Marketscreener.com
Halozyme Therapeutics, Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS - PR Newswire
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - MSN
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - MSN
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Davidson Capital Management Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
State of Alaska Department of Revenue Has $2.22 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Shaker Investments LLC OH Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (HALO) Projected to Post Earnings on Tuesday - MarketBeat
Halozyme rated overweight by Morgan Stanley, diversified revenue cited - MSN
Q1 EPS Estimate for Halozyme Therapeutics Lowered by Analyst - MarketBeat
Halozyme director Connie Matsui to exit board By Investing.com - Investing.com Canada
Halozyme director Connie Matsui to exit board - Investing.com
Halozyme Board Member Connie Matsui Steps Down - TipRanks
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by WCM Investment Management LLC - MarketBeat
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 15 '25 |
Option Exercise |
0.00 |
3,386 |
0 |
177,142 |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Feb 16 '25 |
Option Exercise |
0.00 |
22,205 |
0 |
32,411 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 16 '25 |
Option Exercise |
0.00 |
27,831 |
0 |
33,402 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 15 '25 |
Option Exercise |
0.00 |
1,254 |
0 |
16,734 |
| Torley Helen | PRESIDENT AND CEO |
Feb 16 '25 |
Option Exercise |
0.00 |
109,694 |
0 |
744,548 |
| Torley Helen | PRESIDENT AND CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
13,092 |
0 |
679,836 |
| Henderson Jeffrey William | Director |
Feb 03 '25 |
Sale |
56.30 |
5,000 |
281,517 |
38,611 |
0.27%
3.05%
자본화:
|
볼륨(24시간):